LIXTE Acquires Liora, Gains LiGHT System for High-Rate Proton Therapy
LIXTE Biotechnology Holdings completed a full acquisition of Liora Technologies, gaining exclusive rights to the LiGHT System for image-guided proton therapy. The LiGHT System delivers very high dose rates to deep-seated tumors, cuts installation costs and treatment sessions, and is expected to boost patient throughput.
1. Acquisition Details
On March 10, 2026, LIXTE Biotechnology Holdings finalized the acquisition of Liora Technologies, making it a wholly owned subsidiary. This deal transfers ownership of Liora’s proprietary LiGHT System to LIXTE, positioning the company to enter the proton therapy market.
2. LiGHT System Features
The LiGHT System (Linac for Image Guided Hadron Therapy) delivers very high dose proton beams to deep-seated tumors, enabling unique biological effects. Its design reduces installation costs and lowers the number of treatment sessions required per patient compared with existing proton therapy technologies.
3. Strategic Implications
By integrating the LiGHT System, LIXTE diversifies beyond its PP2A inhibitor drug pipeline and gains a capital equipment offering with recurring revenue potential. The technology is expected to enhance treatment center throughput and expand LIXTE’s addressable market in oncology care.
4. Ongoing Clinical Programs
LIXTE continues proof-of-concept trials for its lead compound LB-100 in ovarian clear cell carcinoma and metastatic colon cancer. The company may explore synergistic approaches combining its pharmacological assets with the newly acquired proton therapy platform.